Cargando…

Personalized medicine: paradigm shift in ALK positive non-small cell lung cancer: a case report

BACKGROUND: Since the identification of multiple therapeutic targets, as is the case of anaplastic lymphoma kinase (ALK) translocation, the paradigm of treating patients with non-small cell lung cancer (NSCLC) has improved. In order to guarantee the possibility of longer survival outcomes with a bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barreira, João Vasco, Mendes, José Leão, Parmanande, Anuraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474633/ https://www.ncbi.nlm.nih.gov/pubmed/37658466 http://dx.doi.org/10.1186/s13256-023-04107-5

Ejemplares similares

Diffuse large B cell lymphoma: cutaneous presentation
por: Ferrão, Joana B, et al.
Publicado: (2018)

Bellini duct carcinoma
por: Falcão, Gil, et al.
Publicado: (2020)

Full recovery of a stage IV cancer patient facing COVID-19 pandemic
por: Parmanande, Anuraj, et al.
Publicado: (2020)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms
por: Barnet, Megan B., et al.
Publicado: (2018)

Pharmacogenetics, Pharmacogenomics and Ayurgenomics for Personalized Medicine: A Paradigm Shift
por: Gupta, Pooja D.
Publicado: (2015)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib
por: El-Osta, Hazem, et al.
Publicado: (2015)

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
por: Passaro, Antonio, et al.
Publicado: (2016)

Personalized medicine: A paradigm shift towards promising health care
por: Annadurai, Kalaivani, et al.
Publicado: (2016)

Sepsis: Personalized Medicine Utilizing ‘Omic’ Technologies—A Paradigm Shift?
por: Itenov, Theis Skovsgaard, et al.
Publicado: (2018)

How I treat ALK-positive non-small cell lung cancer
por: McCusker, Michael G, et al.
Publicado: (2019)

Role of STK11 in ALK-positive non-small cell lung cancer
por: Zhou, Wen, et al.
Publicado: (2022)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
por: Shrestha, N., et al.
Publicado: (2019)

Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition
por: Kerner, Gerald S. M. A., et al.
Publicado: (2016)

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
por: Chia, Puey Ling, et al.
Publicado: (2014)

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
por: Waterhouse, David M., et al.
Publicado: (2020)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
por: Zheng, Bei, et al.
Publicado: (2023)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi, Shipra, et al.
Publicado: (2015)

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer
por: Faugeroux, Vincent, et al.
Publicado: (2014)

Brain Metastasis Mimicking Brain Abscess in ALK-Positive Non-Small-Cell Lung Cancer
por: Sakatani, Toshio, et al.
Publicado: (2019)

Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2021)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors
por: Poddubskaya, Elena, et al.
Publicado: (2019)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
por: Nishio, Makoto, et al.
Publicado: (2018)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
por: Wei, Jiacong, et al.
Publicado: (2018)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
por: Ali, Robert, et al.
Publicado: (2019)

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer
por: Pyo, Kyoung-Ho, et al.
Publicado: (2020)

Clinicopathological features and diagnostic methods of ALK fusion-positive non-small cell lung cancer in Korea
por: Chang, Won Chul, et al.
Publicado: (2020)

Bayesian analysis supports the role of alectinib and ensartinib for ALK‐positive non–small cell lung cancer
por: Rizzo, Alessandro
Publicado: (2023)

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
por: Singh, Abhay, et al.
Publicado: (2020)

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2022)

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Wang, Michelle, et al.
Publicado: (2023)

The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective
por: Cranmer, Holly, et al.
Publicado: (2022)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

Paradigm Shift or Shifting Paradigm for Type 1 Diabetes
por: Nakayama, Maki, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_prp2e3poa5106dtt8mqtjpg5ah